John R. Sims

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease

M. Mintun, M. Pontecorvo, S. Burnham, 2022, JAMA Neurology.

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease

Marzia A. Scelsi, J. Chhatwal, A. Santacruz, 2024, JAMA neurology.

Assessment of Efficacy and Safety of Zagotenemab

A. Lo, I. Higgins, Mark A. Mintun, 2024, Neurology.